Your browser doesn't support javascript.
loading
Feasibility and safety of lumbar puncture in the Parkinson's disease research participants: Parkinson's Progression Marker Initiative (PPMI).
Prakash, Neha; Caspell-Garcia, Chelsea; Coffey, Christopher; Siderowf, Andrew; Tanner, Caroline M; Kieburtz, Karl; Mollenhauer, Brit; Galasko, Douglas; Merchant, Kalpana; Foroud, Tatiana; Chahine, Lana M; Weintraub, Daniel; Casaceli, Cindy; Dorsey, Ray; Wilson, Renee; Herzog, Margaret; Daegele, Nichole; Arnedo, Vanessa; Frasier, Mark; Sherer, Todd; Marek, Ken; Frank, Samuel; Jennings, Danna; Simuni, Tanya.
Affiliation
  • Prakash N; Northwestern University Feinberg School of Medicine, USA. Electronic address: neha.prakash@northwestern.edu.
  • Caspell-Garcia C; The University of Iowa, USA. Electronic address: chelsea-caspell@uiowa.edu.
  • Coffey C; The University of Iowa, USA. Electronic address: christopher-coffey@uiowa.edu.
  • Siderowf A; The University of Pennsylvania, USA. Electronic address: Andrew.siderowf@uphs.upenn.edu.
  • Tanner CM; University of California San Francisco, USA. Electronic address: caroline.tanner@ucsf.edu.
  • Kieburtz K; University of Rochester Medical Center, USA. Electronic address: karl.kieburtz@chet.rochester.edu.
  • Mollenhauer B; Center of Parkinsonism and Movement Disorders Paracelsus-Elena Klinik Kassel and University Medical Center Goettingen, Germany. Electronic address: brit.mollenhauer@med.uni-goettingen.de.
  • Galasko D; University of California San Diego, USA. Electronic address: dgalasko@ucsd.edu.
  • Merchant K; TransThera Consulting, USA. Electronic address: merchant.transthera@gmail.com.
  • Foroud T; Indiana University, USA. Electronic address: tforoud@iu.edu.
  • Chahine LM; University of Pittsburgh, USA. Electronic address: lanachahine@pitt.edu.
  • Weintraub D; The University of Pennsylvania, USA. Electronic address: daniel.weintraub@uphs.penn.edu.
  • Casaceli C; University of Rochester Medical Center, USA. Electronic address: cindy.casaceli@chet.rochester.edu.
  • Dorsey R; University of Rochester Medical Center, USA. Electronic address: ray.dorsey@chet.rochester.edu.
  • Wilson R; Clinical Trial Coordination Center, University of Rochester Medical Center, USA. Electronic address: renee.wilson@chet.rochester.edu.
  • Herzog M; Michael J Fox Foundation, USA.
  • Daegele N; Institute for Neurodegenerative Disorders, USA. Electronic address: ndaegele@invicro.com.
  • Arnedo V; Michael J Fox Foundation, USA. Electronic address: varnedo@michaeljfox.org.
  • Frasier M; Michael J Fox Foundation, USA. Electronic address: mfrasier@michaeljfox.org.
  • Sherer T; Michael J Fox Foundation, USA. Electronic address: tsherer@michaeljfox.org.
  • Marek K; Institute for Neurodegenerative Disorders, USA. Electronic address: kmarek@mnimaging.com.
  • Frank S; Harvard Medical School, Beth Israel Deaconess Medical Center, Parkinson's Disease and Movement Disorders Center, Director of the HDSA Center of Excellence, USA. Electronic address: sfrank2@bidmc.harvard.edu.
  • Jennings D; Denali Therapeutics, USA. Electronic address: jennings@dnli.com.
  • Simuni T; Northwestern University Feinberg School of Medicine, USA. Electronic address: tsimuni@nmff.org.
Parkinsonism Relat Disord ; 62: 201-209, 2019 05.
Article in En | MEDLINE | ID: mdl-30738748
OBJECTIVE: To determine the feasibility, safety and tolerability of lumbar punctures (LPs) in research participants with early Parkinson disease (PD), subjects without evidence of dopaminergic deficiency (SWEDDs) and healthy volunteers (HC). BACKGROUND: Cerebrospinal fluid (CSF) analysis is becoming an essential part of the biomarkers discovery effort in PD with still limited data on safety and feasibility of serial LPs in PD participants. DESIGN/METHODS: Parkinson's Progression Marker Initiative (PPMI) is a longitudinal observation study designed to identify PD progression biomarkers. All PPMI participants undergo LP at baseline, 6, 12 months and yearly thereafter. CSF collection is performed by a trained investigator using predominantly atraumatic needles. Adverse events (AEs) are monitored by phone one week after LP completion. We analyzed safety data from baseline LPs. RESULTS: PPMI enrolled 683 participants (423 PD/196 HC/64 SWEDDs) from 23 study sites. CSF was collected at baseline in 97.5% of participants, of whom 5.4% underwent collection under fluoroscopy. 23% participants reported any related AEs, 68% of all AE were mild while 5.6% were severe. The most common AEs were headaches (13%) and low back pain (6.5%) and both occurred more commonly in HC and SWEDDs compared to PD participants. Factors associated with higher incidence of AEs across the cohorts included female gender, younger age and use of traumatic needles with larger diameter. AEs largely did not impact compliance with the future LPs. CONCLUSIONS: LPs are safe and feasible in PD research participants. Specific LP techniques (needle type and gauge) may reduce the overall incidence of AEs.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Parkinson Disease / Spinal Puncture / Disease Progression Type of study: Clinical_trials / Diagnostic_studies / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: Parkinsonism Relat Disord Journal subject: NEUROLOGIA Year: 2019 Document type: Article Country of publication:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Parkinson Disease / Spinal Puncture / Disease Progression Type of study: Clinical_trials / Diagnostic_studies / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: Parkinsonism Relat Disord Journal subject: NEUROLOGIA Year: 2019 Document type: Article Country of publication: